Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
onCARlytics (CF33-CD19) with Blinatumomab in Advanced Solid Tumors
NCT06063317Phase 1Terminated
- Sponsor
- Imugene
- Start
- Oct 2023
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of CF33-CD19 in solid tumor, sponsored by Imugene. Primary endpoints: Incidence and severity of Adverse Events, Recommended Phase 2 Dose based on lymphocyte subsets at 6 months and 2 more. Started Oct 2023; status: terminated.
02
Drugs
CF33-CD19
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06063317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063317.